Literature DB >> 3851703

Generation of the bioactive kallikrein-derived fragment, C3d-k, by HANE-plasma.

T Seya, S Nagasawa, J P Atkinson.   

Abstract

Recent studies have concluded that after complement activation the final physiologic degradation products of C3 are C3c and the fragment of relative molecular mass (Mr) 42,000 which contains the C3d and C3g domains and was therefore named C3d,g. Using fluorescent labelled C3b as a substrate, we have determined the putative C3d,g ('C3d,g') producing activity of both normal and hereditary angioneurotic oedema (HANE) plasmas. In normal plasmas, the rate of production of C3d,g was 1.0 +/- 0.2 X 10(-10) mol/ml/h and this activity was blocked by antibodies to I. In contrast, HANE, plasmas (deficient in C1INH) showed more than twice as much 'C3d,g' production as normal plasmas and both antibodies to I and kallikrein were required to inhibit this activity. Because of this result, a more sensitive gel system was employed to detect the Mr 42,000 peptide and two 'C3d,g' fragments of approximately equal intensity with Mr of 42,000 and 43,000 were defined. Incubation of purified kallikrein with labelled iC3b produced a C3d,g-like fragment, C3d-k, that aligned with the band of 43,000 Mr generated in HANE plasma. These results indicate that HANE plasma, in contrast to normal plasma, generates the bioactive C3d-k fragment. C1INH blocks the activities of kallikrein and C1s, and C3d-k generation in HANE plasma is probably secondary to the proteolytic activity of kallikrein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3851703      PMCID: PMC1577402     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

Review 1.  Complement ligand-receptor interactions that mediate biological responses.

Authors:  D T Fearon; W W Wong
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

2.  Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: isolation and characterization of a biologically active fragment, C3d,g.

Authors:  T Seya; S Nagasawa
Journal:  J Biochem       Date:  1985-01       Impact factor: 3.387

3.  Polymorphism of human erythrocyte C3b/C4b receptor.

Authors:  T R Dykman; J L Cole; K Iida; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

4.  Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.

Authors:  J L Meuth; E L Morgan; R G DiSipio; T E Hugli
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

5.  Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.

Authors:  A E Davis; R A Harrison; P J Lachmann
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

6.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

Authors:  M Schapira; C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

7.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin.

Authors:  T Fields; B Ghebrehiwet; A P Kaplan
Journal:  J Allergy Clin Immunol       Date:  1983-07       Impact factor: 10.793

8.  Inactivation of kallikrein in human plasma.

Authors:  F van der Graaf; J A Koedam; B N Bouma
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

9.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

10.  Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.

Authors:  M E Medof; K Iida; C Mold; V Nussenzweig
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  1 in total

1.  Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides.

Authors:  B Nilsson; K Nilsson Ekdahl; D Avila; U R Nilsson; J D Lambris
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.